Glycosaminoglycan-degrading glycosidases

Glycosaminoglycan-degrading glycosidases are a specialized group of enzymes, primarily hydrolases, that catalyze the breakdown of complex carbohydrates known as glycosaminoglycans (GAGs), such as heparan sulfate, dermatan sulfate, and hyaluronan [UniProt]. These enzymes are essential for maintaining the structural integrity of the extracellular matrix and ensuring the proper turnover of cellular components within lysosomes [PubMed]. Genetic deficiencies in specific members of this group, such as alpha-L-iduronidase or iduronate-2-sulfatase, lead to Mucopolysaccharidoses (MPS), a family of severe lysosomal storage disorders characterized by progressive multi-systemic damage [NIH]. Conversely, the pathological upregulation of certain glycosidases, most notably heparanase, is frequently observed in malignant tumors, where it promotes metastasis and angiogenesis by degrading physical tissue barriers [PubMed]. Therapeutic strategies include enzyme replacement therapies (ERT) that provide recombinant versions of missing enzymes to patients with MPS, as well as the development of inhibitors to block pathological GAG degradation in oncology [FDA, ClinicalTrials.gov]. Monitoring of these therapies often relies on measuring the concentration of specific GAG fragments in the urine or blood as biomarkers of enzymatic activity [StatPearls].

Other names

Glycosaminoglycan-degrading enzymesMucopolysaccharidasesHeparanasesHyaluronidasesLysosomal glycosidases

Enzyme replacement therapy (restoration of catalytic activity for substrate degradation); Enzyme inhibition (blocking of extracellular matrix degradation to inhibit metastasis).